A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors

Ottimo Pharma Limited

Status and phase

Enrolling

Phase 2

Phase 1

Conditions

Advanced Solid Tumors

Treatments

Drug: OTP-01

Study type

Interventional

Funder types

Industry

Identifiers

NCT07266428

OTP-01-101

U1111-1329-6711 (Other Identifier)

2025-524111-37-00 (EU Trial (CTIS) Number)

Details and patient eligibility

About

The main goals of this clinical trial are to find out what the best dose of the study drug, OTP-01, is for patients with solid tumors through understanding how it is tolerated and any side effects that it may cause. The trial will also see if OTP-01 causes tumors to shrink and how the body processes OTP-01 by measuring drug levels in the blood.

The main questions this study aims to answer are:

What is the recommended dose of OTP-01 for adults with solid tumors?
Is OTP-01 safe and tolerable?
Does OTP-01 reduce tumor growth?

Participants will:

Receive OTP-01 through an infusion into a vein. Doses will be spaced out and never more than once a week.
Have blood tests to evaluate safety and drug levels of OTP-01. These will be done often at first and then less frequently as treatment continues.
Have radiographic scans of their tumor at baseline and during the study at regular intervals.
Have the choice to have an optional tumor biopsy before and after treatment to help researchers understand how OTP-01 affects cancer and the immune system. These biopsies are voluntary and will not affect participation in the study.

Enrollment

170 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Histologically or cytologically confirmed advanced (incurable, recurrent, unresectable, or metastatic) solid tumors.
1. For dose escalation cohort patients: patients must have a tumor type as defined in the protocol. Patients will have progression on or after or intolerance to most recent systemic therapy. Patients must have received approved standard therapy that is available to the patient that is known to confer clinical benefit, unless this therapy is contraindicated, intolerable to the patient, or is declined by the patient. The reason for treatment decline must be clearly documented in the medical record.
2. For backfill cohorts: patients must have a tumor type as defined in the protocol. If patients decline an available standard therapeutic regimen known to confer benefit to enroll on this study, the discussion must be clearly documented in the medical record.
Measurable disease per RECIST v1.1. Additionally, patients with breast or ovarian cancer with non-measurable, evaluable disease are eligible.
ECOG performance status 0-1.
Life expectancy of at least 3 months.
Willing to provide a pretreatment tumor sample (either an archival sample or a sample obtained by pretreatment biopsy).
All toxicity resulting from prior cancer therapies must have resolved to NCI CTCAE v5.0 ≤ Grade 1 or pre-therapy baseline with the exception of alopecia or ≤ Grade 2 neuropathy.
Adequate hematological, renal, and hepatic function.
Other protocol-defined inclusion criteria apply.

Exclusion criteria

Receiving systemic corticosteroids at prednisone-equivalent dose of > 10 mg/day within 4 weeks prior to signing consent. Chronic systemic corticosteroid therapy for physiologic replacement (≤ 10 mg/day of prednisone equivalents) and the use of non-systemic corticosteroids (e.g., inhaled, topical, intra-nasal, intra-articular, or ophthalmic) are permitted
History of Grade 4 allergic or anaphylactic reaction to prior monoclonal antibody therapy or allergic reaction to any excipients within the investigational product
History of toxicity requiring permanent discontinuation of prior cancer immunotherapy
Have an active autoimmune disease that has required systemic treatment in past 2 years (replacement therapy is not considered a form of systemic treatment)
History of organ or stem cell transplant or need for immunosuppressive treatment
Have proteinuria > 2 + (within 7 days prior to initiation of study treatment).
Received any chemotherapy, immunotherapy or investigational anticancer therapy within 3 weeks or 5 half-lives (whichever is shorter; minimum of 2 weeks) prior to first dose of study drug
Definitive radiotherapy within 6 weeks and palliative radiation within 2 weeks prior to the first dose of study drug. If previously irradiated, lesions must have demonstrated clear-cut progression prior to being eligible for evaluation as target lesions
Other protocol and subprotocol-defined exclusion criteria apply